List view / Grid view
The European Commission has approved ONGLYZA® (saxagliptin)...
28 November 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ONGLYZA® (saxagliptin)...
Data presented at this year’s AHA reinforces the established efficacy…
15 November 2011 | By AstraZeneca
Data presented at this year’s AHA reinforces the established efficacy profile of CRESTOR...
AstraZeneca today announced that the FDA approved the orphan drug…
7 April 2011 | By AstraZeneca
AstraZeneca today announced that the FDA approved the orphan drug vandetanib for the treatment of medullary thyroid cancer...
AstraZeneca announced the outcome of the US FDA Advisory Committee…
2 December 2010 | By AstraZeneca
AstraZeneca announced the outcome of the US FDA Advisory Committee meeting...
AstraZeneca and Bristol-Myers Squibb Company today announced that the US…
AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across…
